BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal

Posted: Published on November 16th, 2012

This post was added by Dr. Richardson

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary LifeMap Sciences have announced the launch of LifeMap BioReagents (http://bioreagents.lifemapsc.com/), a new portal offering researchers access to BioTimes research product lines including PureStem human progenitor cell lines, PureStem packages, clinical and research grade human embryonic stem cell lines (hES), HyStem hydrogels, culture media, and cell differentiation kits.

LifeMap Sciences will be the principle marketing and sales arm for BioTimes cell-based products and related reagents for the research community in academia, research hospitals, and biotech and pharma companies. LifeMap Sciences holds the exclusive, worldwide license to market GeneCards (www.genecards.org), with over 12 million page visits per year from hundreds of thousands of unique users worldwide, and MalaCards (www.malacards.org), and plans to launch LifeMap Discovery, its database for biomedical and stem cell research, later this quarter.

LifeMap BioReagents is integrated with the GeneCards, MalaCards, and LifeMap Discovery databases, thereby providing a large number of biomedical researchers accessing these databases a means of identifying stem cell reagents that can enhance research and discovery efforts in a variety of fields, including stem cell research, developmental biology, mechanisms of various human diseases, drug discovery and therapeutic discovery and development.

There has been growing interest in the PureStem and hES cell lines, stated Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. Our ability to provide stable, characterized, pure, and scalable cell lines to the research community and to industry is a big step forwardnot only in the study of stem cells, but also in the understanding of cellular and developmental biology and human disease, and in the discovery of new therapies. Together with our LifeMap Discovery database, researchers will now be able to immediately obtain access to cutting-edge embryonic stem and progenitor cell lines as part of a wealth of developmental and stem cell information that they need for research.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem cell research. This platform includes GeneCards, the leading human gene database; LifeMap Discovery, the database of embryonic development, stem cell research, and regenerative medicine; and MalaCards, the human disease database. LifeMap Sciences also markets PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTimes principal marketing subsidiary for research products, including PureStem human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its LifeMap BioReagents portal. LifeMap Sciences will utilize its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

In a therapeutic discovery collaboration with BioTime, LifeMaps scientists utilize LifeMaps proprietary platform, including LifeMap Discovery, its stem cell database along with the GeneCards and MalaCards integrated database suite, to aid in the development of BioTimes proprietary PureStem human progenitor cell lines into products for the treatment of human diseases, especially degenerative diseases that might be treatable with cell replacement therapies. The LifeMap Discovery platform will be used to select the progenitor cell lines that are most likely to facilitate the development of cell-based regenerative medicine therapies for a wide range of diseases.

About BioTime, Inc.

Visit link:
BioTime and Subsidiary LifeMap Sciences Announce the Launch of LifeMap BioReagents™ Portal

Related Posts
This entry was posted in Stem Cell Human Trials. Bookmark the permalink.

Comments are closed.